🧠 Food for thought

Implications, context, and why it matters.

Novo Nordisk builds an AI setup across vendors

• The OpenAI partnership follows earlier work with Microsoft. Novo Nordisk built a company-wide AI platform on Azure, Microsoft’s cloud computing service, to predict cardiovascular risk 1.
• The company runs Anthropic’s Claude on Amazon Web Services (AWS), Amazon’s cloud platform. The system drafts clinical study reports that sum up results and safety data from drug trials 2.
• For deeper research, the drugmaker is building custom AI models and agents on the Danish Centre for AI Innovation (DCAI)’s NVIDIA-powered Gefion supercomputer. The work looks for correlations between genes, proteins, and diseases 3.

Drug companies become a battleground for cloud and AI vendors

• Novo Nordisk’s enterprise-wide deal moves generative AI from small pilots into broader use across the pharmaceutical business.
• That shift makes drugmakers big customers for Microsoft, AWS, OpenAI, and Anthropic, as they compete for large contracts 2.
• Across the industry, the goal is faster drug discovery. The traditional process has averaged about US$2.5 billion for each new drug 4.
• Some AI-focused drug discovery companies used generative models to propose new drug candidates and reached a successful preclinical phase in as little as 21 days. The preclinical phase is the stage before human testing 4.